Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing.

15 Mar 2016

Drugs to help energy-starved photoreceptors offers new avenue for treating AMD , MacTel

New research from Boston Children's Hospital could potentially change how doctors approach two blinding diseases: 'Wet' age-related macular degeneration (AMD), the leading cause of blindness in the elderly, and macular telangiectasia (MacTel).

15 Mar 2016

Research findings may provide highly effective therapeutic strategy for treatment of Alzheimer's, AMD

For the first time, researchers at LSU Health New Orleans have shown that a protein critical to the body's ability to remove waste products from the brain and retina is diminished in age-related macular degeneration, after first making the discovery in an Alzheimer's disease brain. The research team, led by Walter Lukiw, PhD, Professor of Neurology, Neuroscience and Ophthalmology at LSU Health New Orleans Neuroscience Center, also discovered a key reason, identifying a new treatment target.

8 Mar 2016

Study reveals another clue to workings of trachoma

Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form.

17 Feb 2016

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital.

12 Feb 2016

Apps that test visual function at home can identify vision problems long before traditional tests

Apps that test visual function at home can discover deterioration of the eye's macula lutea long before traditional vision tests. A doctoral thesis at Sahlgrenska Academy explored this issue.

11 Feb 2016

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.

1 Feb 2016

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Age-related macular degeneration is a condition of the macula, a tiny area of the retina at the back of the eye. Your macula is only about the size of the grain of rice, that’s about four millimeters across.

19 Jan 2016

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada recently approved, for the first time in Canada, a clinical project for a Phase I study aimed at treating lymphomas associated with the Epstein-Barr virus (EBV) through adoptive cellular immunotherapy that is specific to EBV.

18 Jan 2016

New discovery may help researchers tackle mitochondrial diseases and age-related diseases

Buck Institute faculty Judith Campisi, PhD, says age researchers need to stop thinking of cellular senescence, now accepted as an important driver of aging, as a single phenotype that stems from genotoxic stress. Research from her lab reveals that cellular senescence, a process whereby cells permanently lose the ability to divide, is also induced by signaling from dysfunctional mitochondria - and that the arrested cells secrete a distinctly different "stew" of biologically active factors in a process unrelated to the damaging free radicals that are created in mitochondria as part of oxygen metabolism.

13 Jan 2016

Ultrafast near-infrared lasers deliver gene therapy to treat macular degeneration

Millions of adults over age 50 struggle each year with vision loss caused by damage to the retina or common macular degeneration.

24 Dec 2015

Study identifies genetic factors that play role in AMD

An international study has identified the number of genetic factors known to play a role in age-related macular degeneration (AMD), the worldwide leading cause of blindness in the elderly.

23 Dec 2015

Study reveals new genetic factors linked to age-related macular degeneration

An international study of about 43,000 people has significantly expanded the number of genetic factors known to play a role in age-related macular degeneration (AMD), a leading cause of vision loss among people age 50 and older.

22 Dec 2015

Scientists identify 52 genetic variations associated with age-related macular degeneration

In one of the latest examples of precision medicine, teams of geneticists from nine countries, involving more than 100 scientists, analyzed the genes of more than 33,000 individuals in the hope of finding genetic variations responsible for age-related macular degeneration (AMD), the leading cause of vision loss among people age 50 or older.

22 Dec 2015

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug -- a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis -- may be too good to be true, according to Arthur M. Feldman, MD, PhD, Executive Dean of the Lewis Katz School of Medicine at Temple University, Chief Academic Officer of the Temple University Health System, and Laura H. Carnell Professor of Medicine at LKSOM.

10 Dec 2015

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD).

15 Nov 2015

L-DOPA drug may delay or prevent age-related macular degeneration

A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD).

10 Nov 2015

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

In a major scientific breakthrough, a drug used to treat Parkinson's and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.

10 Nov 2015

Astellas enters into definitive agreement to acquire Ocata

Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement.

10 Nov 2015

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Anticancer drug restores hearing in neurofibromatosis patients

Drugs to help energy-starved photoreceptors offers new avenue for treating AMD , MacTel

Research findings may provide highly effective therapeutic strategy for treatment of Alzheimer's, AMD

Study reveals another clue to workings of trachoma

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apps that test visual function at home can identify vision problems long before traditional tests

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

New discovery may help researchers tackle mitochondrial diseases and age-related diseases

Ultrafast near-infrared lasers deliver gene therapy to treat macular degeneration

Study identifies genetic factors that play role in AMD

Study reveals new genetic factors linked to age-related macular degeneration

Scientists identify 52 genetic variations associated with age-related macular degeneration

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

L-DOPA drug may delay or prevent age-related macular degeneration

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

Astellas enters into definitive agreement to acquire Ocata

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in